Back to Newsroom

CombiMatrix’s SNP-Based Miscarriage Analysis Test Granted Conditional Approval From New York State Department of Health

IRVINE, Calif., July 31, 2014 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that its SNP-based chromosomal microarray analysis (CMA) test for miscarriage analysis, the CombiSNP™ Array for Pregnancy Loss, or products of conception, has received conditional approval from the New York Department of Health (NYDOH). This approval is for testing on fresh and formalin fixed paraffin embedded (FFPE) patient samples. Last year, the Company’s CMA miscarriage analysis test for fresh tissue was conditionally-approved by NYDOH.

Click here to read more